NEOSONICS The first medical device for non-invasive detection and monitoring of infant meningitis
- Coordinator
- Neos New Born Solutions SL, Spain
- Runs
- 1 December 2022 to 31 August 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €4.1m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190155553
What the project is doing
In the project's own words, from its summary on CORDIS.
Meningitis is a life-threatening disease that can kill in a matter of hours or cause life-long disabilities if not detected promptly. Infants (<12 months) are the most vulnerable population with a compromised immunologic system. Although the incidence is relatively low in industrialised countries, neonatologists only count with lumbar punctures as the gold standard method to detect the disease being invasive, risky and cost-inefficient.
NEOSONICS is a patented first-in-class medical device based on high-frequency ultrasound to non-invasively detect and monitor infant meningitis. The hand-held device is placed on the open fontanelle of a baby and, due to proprietary coupling materials and in-house developed machine learning algorithms, detects the level of white blood cells in the cerebrospinal fluid at a sensitivity of 100%. With NEOSONICS, LPs will be limited to only a few patients with infection (and no LP contraindication) that will be non-invasively assessed with our innovation.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Neos New Born Solutions SL | Madrid | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI